CVS Health stock costs EUR 77.20 with EUR 98.5 billion market value

Published on 10/12/2026 at 15:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock trades at EUR 77.20 on October 12, 2026, versus EUR 77.48. Market value is EUR 98.5 billion, while P/E is 22.79.

Key points in brief

CVS Health stock was EUR 77.20 at Lang & Schwarz on October 12, 2026, 0.36 percent below the October 9 Xetra close.
CVS Health had a EUR 98.5 billion market value and a 22.79 price-to-earnings ratio in the latest quote.
BofA cut its CVS Health target from USD 120 to USD 110 on October 6, 2026, while the next results call is set for November 4, 2026.

Moderner Apothekenverkaufsraum mit Apothekerin und Kundin vor Medikamentenregalen — CVS Health Corp. zeigt fotorealen Apothekenverkaufsraum mit Apothekerin und Kundin, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health (ISIN US1266501006) was trading at EUR 77.20 at Lang & Schwarz on October 12, 2026 at 3:34 p.m. CEST, 0.36 percent below the Xetra close of October 9, 2026 at EUR 77.48. The stock's market value was EUR 98.5 billion, giving investors a clear valuation anchor for the session.

Bid ask spread stays tight

The Lang & Schwarz bid was EUR 76.98 and the ask was EUR 77.42 at the same timestamp. The EUR 0.44 spread puts the immediate quote range around the intraday price at EUR 77.20.

CVS Health's NYSE-listed shares were quoted at USD 86.36 at 1:40 p.m. UTC on October 12, 2026, with a price-to-earnings ratio of 22.85 and a market value of USD 110.2 billion. The euro quote and the US listing are separate market references.

Valuation carries the main signal

The latest CVS Health quote carried a 22.79 price-to-earnings ratio and a 3.00 percent dividend yield. The valuation comparison is more useful than the small daily move because it places the stock against both earnings and shareholder distributions.

Markets Insider reported on October 6, 2026 that BofA analyst Allen Lutz lowered the target from USD 120 to USD 110 while keeping a Buy rating. The dollar target is not converted into a euro comparison.

MarketBeat reported on October 6, 2026 that 22 of 23 analysts rated CVS Health a Buy and that the average 12-month target was USD 107.24.

Comparison with peers

CVS Health Corp.: minus 0.36 percent, P/E 22.79, market capitalization EUR 98.5 billion
UnitedHealth Group (NYSE, USD): minus 0.77 percent, P/E 24.20, market capitalization USD 341.8 billion
The Cigna Group (NYSE, USD): plus 0.21 percent, P/E 11.71, market capitalization USD 74.8 billion

Next results arrive November 4

CVS Health said on October 5, 2026 that it will discuss third-quarter 2026 results on November 4, 2026, at 8:00 a.m. ET. The date gives the market a defined next checkpoint for earnings and guidance.

EUR 77.20 below the Xetra close

At Lang & Schwarz, CVS Health was trading at EUR 77.20 on October 12, 2026 at 3:34 p.m. CEST, minus 0.36 percent versus the Xetra close of October 9, 2026 at EUR 77.48. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.